The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Open accessAbstract
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“Approximately 60% of basal TNBCs bear mutations in p53 (15) and ~90% of mutations in p53 occur in the DNA binding domain.”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationGenome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,144
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,003
Cancer Evolution: Mathematical Models and Computational Inference
Beerenwinkel, N., Schwarz, R. F., Gerstung, M., & Markowetz, F. M. (2014) · Systematic Biology · doi:10.1093/sysbio/syu081 · Cited by 352
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis
Weaver, J. M. J., Ross-Innes, C. S., Shannon, N. B., Lynch, A. G., Forshew, T., Barbera, M., Murtaza, M., Ong, C. J., Lao-Sirieix, P., Dunning, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.3013 · Cited by 348
Self-citationGene expression analysis identifies global gene dosage sensitivity in cancer
Fehrmann, R. S. N., Karjalainen, J. M., Krajewska, M., Westra, H.-J., Maloney, D., Simeonov, A., Pers, T. H., Hirschhorn, J. N., Jansen, R. C., Schultes, E. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3173 · Cited by 347
Targeted exosome‐encapsulated erastin induced ferroptosis in triple negative breast cancer cells
Yu, M., Gai, C., Li, Z., Ding, D., Zheng, J., Zhang, W.-F., Lv, S.-J., & Li, W.-T. (2019) · Cancer Science · doi:10.1111/cas.14181 · Cited by 316
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts
Cassidy, J. W., Caldas, C., & Bruna, A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0727 · Cited by 352
Self-citationExamining the utility of patient-derived xenograft mouse models
Aparicio, S. A. J. R., Hidalgo, M. M., & Kung, A. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3944 · Cited by 352
Self-citationLehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 344
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 343
Weigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 347
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2014) · Cancer · doi:10.1002/cncr.28914 · Cited by 329
Targeting the PI3-kinase pathway in triple-negative breast cancer
Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 339
Breast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K. Y., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 340
Next-generation sequencing and its clinical application
Dahui, Q. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0055 · Cited by 334
Functional impact bias reveals cancer drivers
González-Pérez, A., & López-Bigas, N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks743 · Cited by 335
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai, K., Hung, M., & Yamaguchi, H. (2016) · Europe PMC (PubMed Central) · Cited by 336
Promise of personalized omics to precision medicine
Chen, R., & Snyder, M. P. (2012) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1198 · Cited by 338
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., Kela, I., Hopmans, E. S., Myklebust, J. H., Ji, H. P., et al. (2013) · Blood · doi:10.1182/blood-2012-09-457283 · Cited by 326
Cancer genomics: one cell at a time
Navin, N. E. (2014) · Genome biology · doi:10.1186/s13059-014-0452-9 · Cited by 318
New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Mayer, I. A., Abramson, V. G., Lehmann, B. D., & Pietenpol, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0583 · Cited by 320
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 332
Precision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefèbvre, C., Michiels, S., Bonnefoi, H. R., & André, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 322
Tree inference for single-cell data
Jahn, K., Kuipers, J., & Beerenwinkel, N. (2016) · Genome biology · doi:10.1186/s13059-016-0936-x · Cited by 307
A new genome‐driven integrated classification of breast cancer and its implications
Dawson, S., Rueda, O. M., Aparicio, S. A. J. R., & Caldas, C. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.19 · Cited by 314
Self-citationEcheverria, G. V., Ge, Z., Seth, S., Zhang, X., Jeter-Jones, S. L., Zhou, X., Cai, S., Tu, Y., McCoy, A., Peoples, M. D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0936 · Cited by 307
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
Bashashati, A., Haffari, G., Ding, J., Ha, G., Lui, K., Rosner, J., Huntsman, D. D., Caldas, C., Aparicio, S. A. J. R., & Shah, S. P. (2012) · Genome biology · doi:10.1186/gb-2012-13-12-r124 · Cited by 301
Self-citationUse of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 308
Self-citationPan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Morris, L. G. T., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A. A., Makarov, V., Reis-Filho, J. S., & Chan, T. A.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.7067 · Cited by 307
Wnt signaling in triple-negative breast cancer
Pohl, S., Brook, N., Agostino, M., Arfuso, F., Kumar, A. P., & Dharmarajan, A. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.14 · Cited by 305
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 298
Mroz, E. A., Tward, A. D., Hammon, R. J., Ren, Y., & Rocco, J. W. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001786 · Cited by 294
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 301
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy
Koren, S., & Bentires‐Alj, M. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.031 · Cited by 289
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y. J., Huang, H., Wang, L. H.-C., James, J. L., Balko, J. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26502-6 · Cited by 298
Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Orlic-Milacic, M., Haw, R., Rothfels, K., Wu, G., Croft, D. W., Hermjakob, H., D’Eustachio, P., & Stein, L. D. (2012) · Cancers · doi:10.3390/cancers4041180 · Cited by 281
Patient-derived xenograft models of breast cancer and their predictive power
Whittle, J. R., Lewis, M. T., Lindeman, G. J., & Visvader, J. E. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0523-1 · Cited by 293
Parkin and mitophagy in cancer
Bernardini, J. P., Lazarou, M., & Dewson, G. (2016) · Oncogene · doi:10.1038/onc.2016.302 · Cited by 291
Greulich, H. E., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K., Yun, C., Zhang, X., Lee, S., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 288
Advanced Applications of RNA Sequencing and Challenges
Han, Y., Gao, S., Muegge, K., Zhang, W., & Zhou, B. (2015) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s28991 · Cited by 303
Breast Cancer Molecular Stratification
Russnes, H. G., Lingjærde, O. C., Børresen‐Dale, A., & Caldas, C. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.022 · Cited by 277
Self-citationThe genomic landscape of breast cancer and its interaction with host immunity
Luen, S. J., Virassamy, B., Savas, P. S., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 279
The CRUK IMAXT Grand Challenge Team, O’Flanagan, C. H., Campbell, K. R., Zhang, A. W., Kabeer, F., Lim, J. L., Biele, J., Eirew, P. D., Lai, D., McPherson, A., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1830-0 · Cited by 265
Self-citationCancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 297
Ha, G., Roth, A. J. L., Lai, D., Bashashati, A., Ding, J., Goya, R., Giuliany, R., Rosner, J., Oloumi, A., Shumansky, K., et al. (2012) · Genome Research · doi:10.1101/gr.137570.112 · Cited by 269
Self-citationMechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 287
Molecular classification of breast cancer
Vuong, D., Simpson, P. T., Green, B., Cummings, M. C., & Lakhani, S. R. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1593-7 · Cited by 299
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
Dobrolecki, L. E., Airhart, S., Alférez, D., Aparicio, S. A. J. R., Behbod, F., Bentires‐Alj, M., Brisken, C., Bult, C. J., Cai, S., Clarke, R. B., et al. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9653-x · Cited by 272
Self-citationQuantification of subclonal selection in cancer from bulk sequencing data
Williams, M. J., Werner, B., Heide, T., Curtis, C. N., Barnes, C. P., Sottoriva, A., & Graham, T. A. (2018) · Nature Genetics · doi:10.1038/s41588-018-0128-6 · Cited by 250
Self-citationTumor mutational burden is a determinant of immune-mediated survival in breast cancer
Thomas, A., Routh, E. D., Pullikuth, A., Jin, G., Su, J., Chou, J. W., Hoadley, K. A., Print, C. G., Knowlton, N. S., Black, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490854 · Cited by 266
Genetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudeláková, V., Trojanec, R., & Hajdúch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 270
Lee, K., Kuo, Y., Ho, Y., & Huang, Y. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 270
Hao, J., Lin, D., Dinh, H. Q., Mayakonda, A., Jiang, Y., Chen, C., Jiang, Y., Lü, C., Shi, Z., Xu, X., et al. (2016) · Nature Genetics · doi:10.1038/ng.3683 · Cited by 259
Progression from ductal carcinoma in situ to invasive breast cancer: Revisited
Cowell, C. F., Weigelt, B., Sakr, R. A., Ng, C. K. Y., Hicks, J. B., King, T. A., & Reis-Filho, J. S. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.07.005 · Cited by 259
Wnt signaling in triple negative breast cancer is associated with metastasis
Dey, N., Barwick, B. G., Moreno, C. S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G. M., Tang, W., Catzavelos, C., Kerstann, K. F., Sledge, G. W., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-537 · Cited by 263
Marie-Egyptienne, D. T., Lohse, I., & Hill, R. P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.019 · Cited by 264
Saal, L. H., Vallon-Christersson, J., Häkkinen, J., Hegardt, C., Grabau, D., Winter, C., Brueffer, C., Tang, M.-H. E., Reuterswärd, C., Schulz, R., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0131-9 · Cited by 255
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Advanced Approaches to Breast Cancer Classification and Diagnosis
Zubair, M., Wang, S., & Ali, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.632079 · Cited by 285
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Jamal‐Hanjani, M., Hackshaw, A., Ngai, Y., Shaw, J., Dive, C., Quezada, S. A., Middleton, G., de Bruin, E. C., Quesne, J. P. C. L., Shafi, S., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001906 · Cited by 247
Progress and challenges of immunotherapy in triple-negative breast cancer
Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188593 · Cited by 242
Therapeutic Targeting of Cancers with Loss of PTEN Function
Dillon, L. M., & Miller, T. W. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 246
Inferring clonal evolution of tumors from single nucleotide somatic mutations
Jiao, W., Vembu, S., Deshwar, A. G., Stein, L. D., & Morris, Q. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-35 · Cited by 242
Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239
Fan, J., Lee, H., Lee, S., Ryu, D., Lee, S., Xue, C., Kim, S. J., Kım, K., Barkas, N., Park, P. J., et al. (2018) · Genome Research · doi:10.1101/gr.228080.117 · Cited by 228
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. P. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 239
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 250
Choi, W., Ochoa, A. E., McConkey, D. J., Aine, M., Höglund, M., Kim, W. Y., Real, F. X., Kiltie, A. E., Milsom, I., Dyrskjøt, L., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.010 · Cited by 236
Fast and scalable inference of multi-sample cancer lineages
Popic, V., Salari, R., Hajirasouliha, I., Kashef-Haghighi, D., West, R. B., & Batzoglou, S. (2015) · Genome biology · doi:10.1186/s13059-015-0647-8 · Cited by 231
Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H., Choudhury, A. D., Gydush, G., Reed, S. C., Rhoades, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0033 · Cited by 230
Self-citationXu, G., Chhangawala, S., Cocco, E., Razavi, P., Cai, Y., Otto, J. E., Ferrando, L., Selenica, P., Ladewig, E., Chan, C., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0554-0 · Cited by 234
THetA: inferring intra-tumor heterogeneity from high-throughput DNA sequencing data
Oesper, L., Mahmoody, A., & Raphael, B. J. (2013) · Genome biology · doi:10.1186/gb-2013-14-7-r80 · Cited by 229
The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 231
ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis
Wu, G., Dawson, E. T., Duong, A., Haw, R., & Stein, L. D. (2014) · F1000Research · doi:10.12688/f1000research.4431.2 · Cited by 229
Evolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic Process
Gustafsson, Å. B., & Dorn, G. W. (2018) · Physiological Reviews · doi:10.1152/physrev.00005.2018 · Cited by 235
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. (2014) · Genome biology · doi:10.1186/s13059-014-0431-1 · Cited by 229
Self-citationReconstruction of clonal trees and tumor composition from multi-sample sequencing data
El-Kebir, M., Oesper, L., Acheson-Field, H., & Raphael, B. J. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv261 · Cited by 219
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 233
Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., Nakamura, T., Ueno, M., Ariizumi, S.-I., Hà, N. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7120 · Cited by 223
Ordered and deterministic cancer genome evolution after p53 loss
Baslan, T., Morris, J. P., Zhao, Z., Reyes, J., Ho, Y.-J., Tsanov, K. M., Bermeo, J., Tian, S., Zhang, S., Askan, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05082-5 · Cited by 221
Antecedents and consequences of panic buying: The case of COVID‐19
Prentice, C., Quach, S., & Thaichon, P. (2020) · International Journal of Consumer Studies · doi:10.1111/ijcs.12649 · Cited by 235
Craig, D. W., O'Shaughnessy, J. A., Kiefer, J. A., Aldrich, J., Sinari, S., Moses, T. M., Wong, S., Dinh, J., Christoforides, A., Blum, J. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0781 · Cited by 220
Mroz, E. A., Tward, A. D., Pickering, C. R., Myers, J. N., Ferris, R. L., & Rocco, J. W. (2013) · Cancer · doi:10.1002/cncr.28150 · Cited by 227
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 226
The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
Law, E. K., Sieuwerts, A. M., LaPara, K. S., Leonard, B. C., Starrett, G. J., Molan, A. M., Temiz, N. A., Vogel, R. I., Gelder, M. E. M., Sweep, F. C. G. J., et al. (2016) · Science Advances · doi:10.1126/sciadv.1601737 · Cited by 215
The Consequences of Chromosome Segregation Errors in Mitosis and Meiosis
Potapova, T., & Gorbsky, G. J. (2017) · Biology · doi:10.3390/biology6010012 · Cited by 238
Asleh, K., Riaz, N., & Nielsen, T. O. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02476-1 · Cited by 235
Intratumoral Heterogeneity of the Epigenome
Mazor, T., Pankov, A., Song, J. S., & Costello, J. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.009 · Cited by 217
Self-citationBreast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Testa, U., Castelli, G., & Pelosi, E. (2020) · Medical Sciences · doi:10.3390/medsci8010018 · Cited by 238
Tsimberidou, A. M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S. A., Naing, A., Jankú, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 210
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
Schrörs, B., Boegel, S., Albrecht, C. H., Bukur, T., Bukur, V., Holtsträter, C., Ritzel, C., Manninen, K., Tadmor, A. D., Vormehr, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01195 · Cited by 215
Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer
Jiang, G., Zhang, S., Yazdanparast, A., Li, M., Pawar, A., Liu, Y., Inavolu, S. M., & Cheng, L. (2016) · BMC Genomics · doi:10.1186/s12864-016-2911-z · Cited by 210
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
Gunawardana, J., Chan, F. C., Telenius, A., Woolcock, B. W., Kridel, R., Tan, K. L., Ben‐Neriah, S., Mottok, A., Lim, R. S., Boyle, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2900 · Cited by 216
Self-citationAutophagy in cancer development, immune evasion, and drug resistance
Niu, X., You, Q., Hou, K., Tian, Y., Wei, P., Zhu, Y., Gao, B., Ashrafizadeh, M., Aref, A. R., Kalbasi, A., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101170 · Cited by 244
Cancer: Evolution Within a Lifetime
Gerlinger, M., McGranahan, N., Dewhurst, S. M., Burrell, R. A., Tomlinson, I. P. M., & Swanton, C. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092314 · Cited by 210
Pareja, F. G., Geyer, F. C., Marchiò, C., Burke, K. A., Weigelt, B., & Reis-Filho, J. S. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.36 · Cited by 214
The recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.124 · Cited by 203
The detection and implication of genome instability in cancer
Pikor, L. A., Thu, K. L., Vucic, E. A., & Lam, W. L. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9429-5 · Cited by 216
Mason, J. M., Lin, D., Wei, X., Che, Y., Yao, Y., Kiarash, R., Cescon, D. W., Fletcher, G. C., Awrey, D. E., Bray, M. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.006 · Cited by 202
An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data
Shiraishi, Y., Sato, Y., Chiba, K., Okuno, Y., Nagata, Y., Yoshida, K., Shiba, N., Hayashi, Y., Kume, H., Homma, Y., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt126 · Cited by 202
CD74 and intratumoral immune response in breast cancer
Wang, Z., Milne, K., Webb, J. R., & Watson, P. H. (2016) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
Self-citation
Metadata
- Authors
- Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., Bashashati, A., Prentice, L. M., Khattra, J., Burleigh, A., Yap, D., Bernard, V., McPherson, A., Shumansky, K., Crisan, A., Giuliany, R., Heravi-Moussavi, A., Rosner, J., Lai, D., Birol, I., Varhol, R., Tam, A., Dhalla, N., Zeng, T., Ma, K., Chan, S. K., Griffith, M., Moradian, A., Cheng, S.-W. G., Morin, G. B., Watson, P., Gelmon, K., Chia, S., Chin, S.-F., Curtis, C., Rueda, O. M., Pharoah, P. D., Damaraju, S., Mackey, J., Hoon, K., Harkins, T., Tadigotla, V., Sigaroudinia, M., Gascard, P., Tlsty, T., Costello, J. F., Meyer, I. M., Eaves, C. J., Wasserman, W. W., Jones, S., Huntsman, D., Hirst, M., Caldas, C., Marra, M. A., & Aparicio, S.
- Affiliations
- University of British Columbia (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- University of Southern California (US)
- Cancer Research UK (GB)
- University of Alberta (CA)
- University of California, San Francisco (US)
- Corresponding author
- Shah, Sohrab P.
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- ORCID
- Shah, Sohrab P.
- Roth, Andrew
- Ha, Gavin
- Zhao, Yongjun
- Turashvili, Gulisa
- Ding, Jiarui
- Haffari, Gholamreza
- Bashashati, Ali
- Prentice, Leah M.
- Burleigh, Angela
- Yap, Damian
- McPherson, Andrew
- Crisan, Anamaria
- Rosner, Jamie
- Lai, Daniel
- Varhol, Richard
- Tam, Angela
- Griffith, Malachi
- Moradian, Annie
- Cheng, S.-W. Grace
- Morin, Gregg B.
- Watson, Peter
- Gelmon, Karen
- Chia, Stephen
- Chin, Suet-Feung
- Curtis, Christina
- Rueda, Oscar M.
- Pharoah, Paul D.
- Damaraju, Sambasivarao
- Mackey, John
- Harkins, Timothy
- Gascard, Philippe
- Tlsty, Thea
- Costello, Joseph F.
- Meyer, Irmtraud M.
- Eaves, Connie J.
- Wasserman, Wyeth W.
- Jones, Steven
- Huntsman, David
- Hirst, Martin
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-04
- Volume
- 486
- Issue
- 7403
- Pages
- 395-399
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3863681
- OpenAlex
- W2063382533
- Cited by
- 1,967
- References
- 23
- Citations by year
- 2026: 40 · 2025: 61 · 2024: 71 · 2023: 131 · 2022: 132 · 2021: 119 · 2020: 131 · 2019: 120 · 2018: 135 · 2017: 173 · 2016: 179 · 2015: 198 · 2014: 199 · 2013: 201 · 2012: 76
- FWCI
- 71.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Canada's Michael Smith Genome Sciences Centre
- Canadian Breast Cancer Research Alliance
- Michael Smith Health Research BC
- Cancer Research UK
- National Institute for Health and Care Research (NF-SI-0611-10154)
- Cure Brain Cancer Foundation
- BC Cancer Foundation
- National Institutes of Health
- Imperial Experimental Cancer Medicine Centre
- BC Cancer Agency
- National Institute of General Medical Sciences (R01GM084875)
- National Institute of Environmental Health Sciences (U01ES017154)
- Congressionally Directed Medical Research Programs
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- triple-negative breast cancer, clonal evolution, somatic mutations, copy number variation, cancer genomics, TP53 mutation, PIK3CA mutation, PTEN mutation, basal subtype, tumor progression, founder mutation, clonal heterogeneity
- MeSH terms
- Alleles, Breast Neoplasms, Clone Cells, DNA Mutational Analysis, Female, Genotype, Humans, Mutation, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Point Mutation, Sequence Analysis, RNA, Disease Progression, Evolution, Molecular, Gene Expression Profiling, INDEL Mutation, DNA Copy Number Variations, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
